Prof. Akiko Iwasaki Profile picture
Mar 3 16 tweets 6 min read Read on X
Delighted to share our latest work on #longCOVID - sex differences in symptoms and immune signatures. Led by @SilvaJ_C @taka_takehiro @wood_jamie_1 et al. with @LeyingGuan & @PutrinoLab. We find a striking inverse correlation btw testosterone levels and symptom burden👇🏼 (1/)

medrxiv.org/content/10.110…
This work leverages data from our recent Mount Sinai-Yale long COVID "MY-LC" study with the @PutrinoLab. This time, we asked the question, "Are there differences in symptoms and immune signatures of ♀️ vs. ♂️ with LC"? (2/)

nature.com/articles/s4158…
Image
While some symptoms were equally frequent in females and males, many were more frequent in females (e.g., swelling, headaches, muscle pain, cramps) than males. The top distinguishing symptoms of LC status by sex were hair loss in females and sexual dysfunction in males. (3/) Image
What organ-specific symptoms correlate with one another in females vs. males? In females (left), temperature-related symptoms and musculoskeletal symptoms were strongly associated with other symptoms. In males (right), ear nose and throat (ENT) symptoms were most associated with other symptoms. (4/)Image
What about immune signatures? Females with LC had increases in exhausted and cytokine-secreting T cells and antibodies against lytic antigens from herpesviruses, suggestive of recent reactivation. (5/) Image
In contrast, males with LC had elevated NK cells, reduced monocytes and plasmacytoid dendritic cells. They also had increases in TGF-beta, APRIL and IL-8, features not significantly different in females with LC. (6/) Image
Females with LC had significantly lower testosterone levels. Using logistic regression, @SilvaJ_C found testosterone to be the top negative hormone predictor of LC status in females based on per unit odds ratio. Thus, in females, the lower the testosterone, the more likely to have LC. (7/)Image
In males, those with LC had lower levels of estradiol, and estradiol was found to be the top negative predictor hormone of LC status. (8/) Image
Next, @silvaJ_C took a different machine-learning approach. This time he divided the MY-LC cohort into training vs. testing sets. He took cellular profiles and plasma factors but excluded hormones within females and males separately and calculated sex-specific immune scores. (9/) Image
This strategy successfully predicted LC status in females (86% accuracy) and males (87% accuracy). Meaning that cellular and soluble immune features alone can distinguish those with LC in both sexes pretty accurately. (10/) Image
Using this modeling strategy, we found that female LC immune signatures were associated with higher symptom burden, organ involvement and dysautonomia in males with LC. Conversely, male LC immune signatures correlated with lower symptom burden, dysautonomia and neurocognitive symptoms in females with LC! Overall, male LC immune signatures meant less symptoms in LC. (11/)Image
So what is driving the male LC immune signatures? Testosterone! Regardless of sex, those with higher testosterone levels had higher male LC immune signatures. Those with lower testosterone had higher female LC immune signatures. (12/) Image
Finally, testosterone levels could significantly predict not just LC status but also symptom burden and organ system involvement in individuals with LC irrespective of sex. (13/) Image
To summarize, we find significant differences in symptoms and immune signatures in females vs. males with long COVID. (14/) Image
There is a fascinating backstory to this study I wish to share (with permission). In August of 2022, @tarazupancic DM me about a profound improvement in the long COVID symptoms of her child after receiving testosterone for gender-affirming care. I discussed this at our weekly long COVID lab science meeting. This is how it all started. So grateful to Tara for sharing this key insight with us 🙏🏼🙏🏼 (15/)
As always, this was a huge undertaking by many dedicated scientists and clinicians, and the amazing contributions of patients who donated their time, effort and blood samples. Incredible teamwork with the Mount Sinai team @PutrinoLab. Kudos to @SilvaJ_C, @taka_takehiro, @wood_jamie_1, @peowenlu, @S_Tabachnikova, @JeffGehlhausen, @KerrieGreene_ , @bornali_27, Valter Silva Monteiro, @carolilucas, @rahuldhodapkar, @marioph13, Kathy Kamath, @tianyangmao, Dayna Mccarthy, @RMedzhitov, @david_van_dijk, @hmkyale and @LeyingGuan!!Image

• • •

Missing some Tweet in this thread? You can try to force a refresh
 

Keep Current with Prof. Akiko Iwasaki

Prof. Akiko Iwasaki Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

PDF

Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @VirusesImmunity

Jun 19
Sharing our new study by @keylas3, @SilvaJ_C, Rafael Bayarri Olmos et al (with T. Horvath & @PutrinoLab) showing that a passive transfer of IgG from patients with #longCOVID into mice recapitulates ⬆️ pain and other symptoms 🧵 (1/)

medrxiv.org/content/10.110…
Long COVID disease pathogenesis includes persistent SARS-CoV-2 virus, dysbiosis, herpesvirus reactivation, autoimmunity, and others. In this study, we focus on the role of autoantibodies. (2/) Image
Among the original Mount Sinai-Yale Long COVID study participants 👇🏼 (with @PutrinoLab), we focused on patients with high neurological symptom burden (n=55), and compared antibodies with convalescent controls (n=42) or uninfected controls (n=39). (3/)
nature.com/articles/s4158…
Read 20 tweets
Jun 19
What determines whether someone gets infected or not after exposure to SARS-CoV-2? A new study by Lindeboom et al examined this question with COVID-19 human challenge study. @BenIsraelow and I summarize their key findings in this News & Views 🧵 (1/)
nature.com/articles/d4158…
The study: 16 healthy young volunteers with no prior infection or vaccination were inoculated nasally with a low dose of pre-Alpha SARS-CoV-2 strain. Interestingly, only 6 had sustained infection, 3 had transient, and 7 had abortive infection at this dose. (2/) nature.com/articles/s4158…Image
The three infection outcomes allowed investigation of key features associated with susceptibility vs. resistance. Higher baseline expression of HLA-QA2 mRNA was associated with COVID resistance. Early nasal interferon I response was seen in those with transient infection. (3/) Image
Read 10 tweets
Apr 22
Preventing infection is the best way to avoid diseases like #PAIS. A new study from our team @tianyangmao, Jooyoung Kim, @marioph13 et al shows that a generic antibiotic neomycin acts on the host immune system in the👃🏽to trigger antiviral resistance. (1/)🧵
pnas.org/doi/10.1073/pn…
This work is inspired by @SmitaGopinath et al who showed that an antibiotic class called aminoglycosides has an unusual antiviral property. Aminoglycosides including neomycin trigger interferon-stimulated genes through a TLR3-dependent mechanism. (2/)
ncbi.nlm.nih.gov/pmc/articles/P…
In our current study, we showed that nasal application of neomycin in mice one day before infection reduces viral load and disease burden after the SARS-COV-2 challenge. @tianyangmao (3/) Image
Read 11 tweets
Jan 13
In this prospective observational study, we examined changes in symptoms & immune phenotypes in vaccine-naïve people with #LongCovid after COVID-19 vaccination. Due to the timing of the initiation of this study, we were only able to recruit 16 people. However, the insights we gained are intriguing. Led by @connorbgrady, @bornali_27, @silva_JC, @hmkyale et al. (1/)
medrxiv.org/content/10.110…Image
This study was initiated in collaboration with @Survivor_Corps @dianaberrent based on their Facebook poll showing that 40% of respondents with self-reported Long COVID had mild to full symptom resolution after vaccination while 14% reported worsening of their symptoms. (2/)
doi.org/10.1101/2021.0…
In addition, evidence from other patient advocate groups, including @patientled and @longCovidSOS, and from @DanielGriffinMD, was emerging at the time on the impact of COVID vaccines in people with long COVID. (3/)
Read 19 tweets
Sep 25, 2023
So pleased to report that our Mount Sinai-Yale long COVID (MY-LC) paper with @putrinolab & others is now published!! Proud of the hard work of all who contributed. We found biological signatures that can distinguish people with vs. without #longCOVID (1/) nature.com/articles/s4158…
Question being asked: are there circulating cells & immune factors that are distinct in people with #longCOVID (LC) vs. those who recovered from COVID (convalescent control; CC) or those who never had COVID (healthy control; HC)? We studied 268 participants to address this. (2/) Image
Most participants were infected during the first wave in 2020, and studied on average about a year after the infection. Most were not hospitalized at acute phase and ~2/3 were female. We examined plasma factors, blood leukocytes & antibodies to SARS2, other viruses & self (3/) Image
Read 11 tweets
Aug 27, 2023
A short 🧵on a recent study by @MaggieLind2 with @MHitchingsEpi @datcummings Albert Ko et al. Data show that immunity induced by vaccines, prior infection or both (hybrid) protects against SARS-CoV-2 infection when viral exposure is low to moderate (1/)

nature.com/articles/s4146…
Question being asked: What is the risk of becoming *infected* with SARS-CoV-2 after developing immunity following a vaccine, prior infection, or both if exposure to the virus is very high, moderate, or low? They did not study the severity of symptoms. (2/)
How? The authors used the existing database of the Connecticut Department of Correction, where infection data based on high frequency of testing for SARS-CoV-2 on ~9300 residents across 13 facilities were available. (3/)
Read 9 tweets

Did Thread Reader help you today?

Support us! We are indie developers!


This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Don't want to be a Premium member but still want to support us?

Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal

Or Donate anonymously using crypto!

Ethereum

0xfe58350B80634f60Fa6Dc149a72b4DFbc17D341E copy

Bitcoin

3ATGMxNzCUFzxpMCHL5sWSt4DVtS8UqXpi copy

Thank you for your support!

Follow Us!

:(